BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 98 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65 | -24.4% | 10,300 | -12.9% | 0.01% | -41.7% |
| Q2 2023 | $86 | – | 11,825 | +5812.5% | 0.01% | – |
| Q1 2023 | $0 | -100.0% | 200 | -89.3% | 0.00% | -100.0% |
| Q4 2022 | $20 | -99.9% | 1,867 | -44.6% | 0.00% | 0.0% |
| Q3 2022 | $33,000 | -36.5% | 3,367 | -21.1% | 0.00% | -50.0% |
| Q2 2022 | $52,000 | +40.5% | 4,267 | -54.1% | 0.00% | +100.0% |
| Q1 2022 | $37,000 | -19.6% | 9,300 | +272.0% | 0.00% | 0.0% |
| Q4 2021 | $46,000 | -48.3% | 2,500 | -16.7% | 0.00% | -50.0% |
| Q3 2021 | $89,000 | +2.3% | 3,000 | -23.1% | 0.00% | 0.0% |
| Q2 2021 | $87,000 | -38.3% | 3,900 | -3.5% | 0.00% | -42.9% |
| Q1 2021 | $141,000 | -58.8% | 4,040 | -67.9% | 0.01% | -53.3% |
| Q4 2020 | $342,000 | +37.9% | 12,600 | -49.7% | 0.02% | -6.2% |
| Q3 2020 | $248,000 | -59.1% | 25,048 | +36.1% | 0.02% | -60.0% |
| Q2 2020 | $607,000 | +291.6% | 18,406 | +25.0% | 0.04% | +400.0% |
| Q1 2020 | $155,000 | – | 14,722 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |